Comparative Efficacy and Safety of IgAN Treatments: A Bayesian Network Meta-Analysis (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #TH-PO0455; Pres time: Oct 22, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Results Eleven RCTs (n=3,298) with ten treatments and protocols were included: Sibeprenlimab, Atacicept, Iptacopan, Mycophenolate mofetil, Budesonide, STOP-IgAN, Methylprednisolone, Sparsentan, Atrasentan, and standard of care (SOC). No treatment differed significantly from SOC for IEs. These findings highlight the need for direct head-to-head RCTs to confirm the comparative efficacy and safety profiles suggested by indirect network estimates."
Retrospective data • Glomerulonephritis • IgA Nephropathy • Renal Disease • CFB
|
|
Vinodh Mechery; Gabriel Contreras; Sanjana Kota
|